Biosimilars

USP and Synthetic Therapeutic Peptides

USP and SyntheticTherapeutic Peptides

Anita Szajek, Ph.D., principal scientific liaison to USP’s Expert Panel on Therapeutic Peptides, examines therapeutic peptides, the transition from recombinant to synthetic manufacturing routes, and regulatory and quality-related questions.

Share

Pharmaceutical Compliance: A Conversation with Chuck Bates

Pharmaceutical Compliance Manager

There’s a chance you may work in pharma and not know about USP, but rest assured your compliance manager does. What, exactly, does your compliance manager do?  How does he or she interact with USP?  To find out, we asked award-winning source Charles “Chuck” Bates from Sandoz—recent recipient of the Novartis Group Advanced Sciences & Technologies-Quality Control Award for Individual Commitment to Excellence.

Share

Pages